Code of Massachusetts Regulations
310 CMR - DEPARTMENT OF ENVIRONMENTAL PROTECTION
Title 310 CMR 40.0000 - Massachusetts Contingency Plan
Subpart I - RISK CHARACTERIZATION
Section 40.0993 - Method 3 Human Health Risk Characterization
Current through Register 1531, September 27, 2024
Under Method 3, the risk of harm to human health shall be characterized for all current and reasonably foreseeable Site Activities and Uses identified in 310 CMR 40.0923, as follows:
(1) The site, receptor and exposure information described in 310 CMR 40.0901 through 310 CMR 40.0920 shall be identified and documented.
(2) The groundwater and soil categories applicable to the disposal site shall be identified and documented, as described in 310 CMR 40.0930. The groundwater and soil categories shall be considered as general indicators of exposure potential in a Method 3 evaluation.
(3) All applicable or suitably analogous health standards shall be identified in the documentation of the Method 3 Risk Characterization. The MCP Method 1 Groundwater and Soil Standards listed in 310 CMR 40.0970 are not considered applicable or suitably analogous, as those standards represent an alternative approach to Method 3. The list of potentially applicable or suitably analogous standards includes, but is not limited to:
(4) The frequency, duration and intensity of exposure to each oil and/or hazardous material at the disposal site for each receptor at each Exposure Point shall be determined and documented, considering the current and reasonably foreseeable Site Activities and U ses identified for the disposal site. The magnitude of each receptor's total exposure to the oil and/or hazardous material at the disposal site is calculated in a manner which provides a conservative estimate of the potential exposures. Assessments conducted using a probabilistic analysis shall identify the 95th percentile estimate of each receptor's potential exposure.
(5) For each identified Human Receptor, cumulative cancer risks and cumulative non-cancer risks shall be calculated. Chemical-specific toxicity information used to estimate the cancer and non-cancer risks shall be identified and documented, and the selection of this information shall take into account standards and guidance published by the Department. Primary consideration shall be given to information developed by the Massachusetts Department of Environmental Protection for the purpose of conducting such risk assessments. Examples of such toxicity information include:
(6) When identifying toxicity values for use in a Method 3 Risk Characterization, toxicity values developed by MassDEP shall be used.
(7) If an applicable toxicity value is not listed at 310 CMR 40.0993(6), technical justification for the value selected must be provided. Preferential consideration shall be given to sources of toxicity values in accordance with the following hierarchy:
(8) For receptors who may be exposed to mixtures of oil and/or hazardous material, or through multiple Exposure Pathways at the disposal site, the cumulative risk shall reflect those multiple exposures. Risk estimates are presumed to be additive unless an alternative mechanism is demonstrated to be appropriate.
(9) Risk calculations performed using a probabilistic analysis shall identify the cumulative cancer and non-cancer risks associated with the 95th percentile estimate of exposure.
(10) The Cumulative Receptor Cancer Risks shall be compared to a Cumulative Cancer Risk Limit which is an Excess Lifetime Cancer Risk equal to one-in-one hundred thousand. Cumulative Receptor Non-cancer Risks shall be compared to a Cumulative Non-cancer Risk Limit which is a Hazard Index equal to one. Estimated Exposure Point Concentrations shall be compared to any applicable or suitably analogous standards.
(11) A condition of no significant risk of harm to human health exists or has been achieved if:
(12) The documentation of the Method 3 human health Risk Characterization shall clearly state whether or not a condition of no significant risk of harm to human health exists or has been achieved, based upon the criteria described in 310 CMR 40.0993(11).
(13) All mathematical equations used to calculate cumulative receptor cancer and non-cancer risks shall be clearly presented and documented.